Radiopharmaceutical pylarify
Active Awarded
- Contract number
- 36C24526N0180
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,811,577
Award facts
- Contract value 20% obligated
-
- $1,811,577.44 Current, with exercised options
- $9,057,887.20 Potential, with all options
- Completion date 16% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging Inc., was awarded a delivery order contract on January 2, 2026, to supply PYLARIFY (piflufolastat F-18), a diagnostic radiopharmaceutical used in positron emission tomography (PET) imaging for prostate cancer detection. The contract, issued by the Department of Veterans Affairs through Veterans Integrated Service Network 5, carries a firm fixed-price ceiling value of $9.06M with an ultimate completion date of January 1, 2031. The product will be supplied from the vendor's facility in North Billerica, Massachusetts. This delivery order was issued without a set-aside designation and operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a master vehicle that streamlines procurement of critical medical imaging agents across federal healthcare systems.
The contract represents a continuation of the company's significant role as a primary supplier of radiopharmaceuticals to the VA and other federal healthcare agencies. Lantheus Holdings, the parent company, maintains substantial indefinite delivery vehicles with the VA and Defense Health Agency, with potential values reaching $290M under its Federal Supply Schedule contract. PYLARIFY and related radiopharmaceuticals delivered through these contract vehicles support medical imaging programs across VA medical centers and military treatment facilities nationwide, enabling critical diagnostic capabilities for prostate cancer detection and localization among veteran and military beneficiary populations.
Quick answers
Who was awarded contract 36C24526N0180?
36C24526N0180 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on January 2, 2026.
How much is contract 36C24526N0180 worth?
The government has obligated $1,811,577 on 36C24526N0180. Its potential value, with all options, is $9,057,887.
Is contract 36C24526N0180 an order under another contract?
Yes. 36C24526N0180 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0180 competed?
The extent of competition for 36C24526N0180 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award